CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine - The ROPA-DOP Trial Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

Clinical TrialNov. 17, 2019

JOURNAL:Circulation. Article Link

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

MN Kosiborod, PJhund, KF Docherty et al. Keywords: dapagliflozin; HFrEF; quality of life; cardiovascular outcomes

FULL TEXT PDF